LIVIVO - Search results -

Search results

Result 1 - 10 of total 12

Search options

Article ; Online: NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications.

Deshotels, Leigh / Safa, Firas M / Saba, Nakhle S

International journal of molecular sciences

2023 Volume 24, Issue 12

Abstract: Despite major progress in mantle cell lymphoma (MCL) therapeutics, MCL remains a deadly disease with a median survival not exceeding four years. No single driver genetic lesion has been described to solely give rise to MCL. The hallmark translocation t( ... ...

Abstract	Despite major progress in mantle cell lymphoma (MCL) therapeutics, MCL remains a deadly disease with a median survival not exceeding four years. No single driver genetic lesion has been described to solely give rise to MCL. The hallmark translocation t(11;14)(q13;q32) requires additional genetic alterations for the malignant transformation. A short list of recurrently mutated genes including ATM, CCND1, UBR5, TP53, BIRC3, NOTCH1, NOTCH2, and TRAF2 recently emerged as contributors to the pathogenesis of MCL. Notably, NOTCH1 and NOTCH2 were found to be mutated in multiple B cell lymphomas, including 5-10% of MCL, with most of these mutations occurring within the PEST domain of the protein. The NOTCH genes play a critical role in the early and late phases of normal B cell differentiation. In MCL, mutations in the PEST domain stabilize NOTCH proteins, rendering them resistant to degradation, which subsequently results in the upregulation of genes involved in angiogenesis, cell cycle progression, and cell migration and adhesion. At the clinical level, mutated NOTCH genes are associated with aggressive features in MCL, such as the blastoid and pleomorphic variants, a shorter response to treatment, and inferior survival. In this article, we explore in detail the role of NOTCH signaling in MCL biology and the ongoing efforts toward targeted therapeutic interventions.
MeSH term(s)	Adult ; Humans ; Lymphoma, Mantle-Cell/pathology ; Mutation ; Signal Transduction ; Translocation, Genetic ; Genes, cdc
Language	English
Publishing date	2023-06-17
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms241210280
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.

Paillassa, Jérôme / Safa, Firas

Leukemia research reports

2021 Volume 17, Page(s) 100282

Abstract: Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated with conventional therapies. Significant efforts have been made in recent years to bring a broad ... ...

Abstract	Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated with conventional therapies. Significant efforts have been made in recent years to bring a broad spectrum of novel targeted therapies, the most noteworthy of which is chimeric antigen receptor T-cell therapy (CAR-T). Not all patients are eligible for CAR-T given the relatively high risk of complications and limited availability. Here we discuss promising novel biologic therapies that have been introduced in the last few years and go over ongoing clinical trials in the field.
Language	English
Publishing date	2021-12-10
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2706248-X
ISSN	2213-0489
ISSN	2213-0489
DOI	10.1016/j.lrr.2021.100282
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.

Paillassa, Jérôme / Safa, Firas / Troussard, Xavier

Therapeutic advances in hematology

2022 Volume 13, Page(s) 20406207221090886

Abstract: Hairy cell leukemia (HCL) and HCL-like disorders such as hairy cell leukemia variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL) are rare indolent B-cell malignancies. Purine analogs (PNAs), alone or in association with rituximab (R), are the ... ...

Abstract	Hairy cell leukemia (HCL) and HCL-like disorders such as hairy cell leukemia variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL) are rare indolent B-cell malignancies. Purine analogs (PNAs), alone or in association with rituximab (R), are the standard of care for HCL in the first-line setting. However, PNAs are toxic and patients may become resistant to these drugs. Therefore, new therapeutic strategies are needed. Several recent Plain language summary: Bruton's tyrosine kinase (BTK) inhibitors (BTKi) in hairy cell leukemia (HCL) and variant-type HCL
Language	English
Publishing date	2022-04-13
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2585183-4
ISSN	2040-6215 ; 2040-6207
ISSN (online)	2040-6215
ISSN	2040-6207
DOI	10.1177/20406207221090886
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis: A brief case report.

Kwaramba, Tendai / Lewis, Brian / Burks, Bruce / Ruiz, Bernardo / Iyer, Swaminathan P / Safa, Firas

Leukemia research reports

2022 Volume 17, Page(s) 100292

Abstract: Large granular lymphocytic leukemia (LGL) is a rare lymphoproliferative disorder that involves the T-cell lineage in around 85% of cases and NK-cell lineage in 15%. Most patients require treatment at some point of their disease trajectory to address ... ...

Abstract	Large granular lymphocytic leukemia (LGL) is a rare lymphoproliferative disorder that involves the T-cell lineage in around 85% of cases and NK-cell lineage in 15%. Most patients require treatment at some point of their disease trajectory to address clinical symptomatology largely pertaining to cytopenia. While immunosuppression represents the backbone of LGL therapy, there is no consensus on the best next line following failure of immunosuppression. Here we present a case of LGL-associated cytopenia in a 73-year-old male refractory to immunosuppression, treated with adjunct erythropoietin alpha (EPO) with a marked response. Our case suggests that EPO therapy may provide therapeutic benefit in refractory LGL cases when used in conjunction with immunosuppressive therapy.
Language	English
Publishing date	2022-02-09
Publishing country	Netherlands
Document type	Case Reports
ZDB-ID	2706248-X
ISSN	2213-0489
ISSN	2213-0489
DOI	10.1016/j.lrr.2022.100292
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.

Safa, Firas M / Rasmussen, Terri / Fontan, Lorena / Xia, Min / Melnick, Ari / Wiestner, Adrian / Lobelle-Rich, Patricia / Burger, Jan A / Mouawad, Yara / Safah, Hana / Flemington, Erik K / Saba, Nakhle S

Haematologica

2024 Volume 109, Issue 5, Page(s) 1348–1358

Abstract: B-cell acute lymphoblastic leukemia (B-ALL) remains a hard-to-treat disease with a poor prognosis in adults. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a para-caspase required for B-cell receptor (BCR)-mediated NF-κB ... ...

Abstract	B-cell acute lymphoblastic leukemia (B-ALL) remains a hard-to-treat disease with a poor prognosis in adults. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a para-caspase required for B-cell receptor (BCR)-mediated NF-κB activation. Inhibition of MALT1 in preclinical models has proven efficacious in many B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma and diffuse large B-cell lymphoma. We sought to examine the role of MALT1 in B-ALL and determine the biological consequences of its inhibition. Targeting MALT1 with both Z-VRPR-fmk and MI-2 efficiently kills B-ALL cells independent of the cell-of-origin (pro, pre, mature) or the presence of the Philadelphia chromosome, and spares normal B cells. The mechanism of cell death was through apoptotic induction, mostly in cycling cells. The proteolytic activity of MALT1 can be studied by measuring its ability to cleave its substrates. Surprisingly, with the exception of mature B-ALL, we did not detect cleavage of MALT1 substrates at baseline, nor after proteasomal inhibition or following activation of pre-BCR. To explore the possibility of a distinct role for MALT1 in B-ALL, independent of signaling through BCR, we studied the changes in gene expression profiling following a 24-hour treatment with MI-2 in 12 B-ALL cell lines. Our transcriptome analysis revealed a strong inhibitory effect on MYC-regulated gene signatures, further confirmed by Myc protein downregulation, concomitant with an increase in the Myc degrader FBXW7. In conclusion, our evidence suggests a novel role for MALT1 in B-ALL through Myc regulation and provides support for clinical testing of MALT1 inhibitors in B-ALL.
MeSH term(s)	Humans ; Apoptosis ; Caspases/metabolism ; Cell Line, Tumor ; Gene Expression Profiling ; Molecular Targeted Therapy ; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein/metabolism ; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein/antagonists & inhibitors ; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein/genetics ; Neoplasm Proteins/genetics ; Neoplasm Proteins/metabolism ; Neoplasm Proteins/antagonists & inhibitors ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology
Chemical Substances	Caspases (EC 3.4.22.-) ; MALT1 protein, human (EC 3.4.22.-) ; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein (EC 3.4.22.-) ; Neoplasm Proteins
Language	English
Publishing date	2024-05-01
Publishing country	Italy
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2023.283178
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Establishment and characterization of a new mantle cell lymphoma cell line with a NOTCH2 mutation, Arbo.

Safa, Firas / Rasmussen, Terri / Lobelle-Rich, Patricia / Collier, Stephanie / Milligan, Nicholas / Schmeig, John / Schmid, Janet / Wiewiorowski, Carol / Totaro, Denise / Brown, Theresa C / Satyavarapu, Ishwarya / Badoo, Melody / Ungerleider, Nathan / Flemington, Erik K / Safah, Hana / Saba, Nakhle S

EJHaem

2022 Volume 3, Issue 4, Page(s) 1326–1329

Abstract: Cell lines represent an essential tool used in preclinical research. Most hematologic malignancies have a wide array of cell lines representing their respective molecular and pathologic spectra. In mantle cell lymphoma (MCL), cell lines become ... ...

Abstract	Cell lines represent an essential tool used in preclinical research. Most hematologic malignancies have a wide array of cell lines representing their respective molecular and pathologic spectra. In mantle cell lymphoma (MCL), cell lines become specifically valuable in view of the heterogeneity of this disease. Unfortunately, the number of MCL cell lines that are available for the research community remains small, with only nine cell lines available for purchase through the American Type Culture Collection (ATCC). We have established a novel blastoid MCL cell line, isolated from the malignant pleural effusion of a 69-year-old male with refractory MCL. Arbo was fully characterized with cytogenetics, immunophenotyping, whole exome sequencing and drug sensitivity assays. One of the most notable mutations identified in Arbo (but not in normal tissue) was the missense mutation NOTCH2 R2400, which has been proposed as a clinically significant mutation in MCL seen in 5% of cases. NOTCH2 R2400 results in a truncated Notch2 protein, leading to a more stable and active protein. Using pharmacologic inhibition of Notch2, we showed a dependence of Arbo on NOTCH2 signaling, as well as a link between CD23 expression on Arbo and NOTCH2 activity. Arbo represents a NOTCH2 mutated model that is useful in MCL as well as other lymphomas with such mutation. We plan to deposit Arbo at the ATCC to be available for the research community.
Language	English
Publishing date	2022-09-20
Publishing country	United States
Document type	Journal Article
ISSN	2688-6146
ISSN (online)	2688-6146
DOI	10.1002/jha2.580
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies.

Niu, Alex / Ning, Bo / Socola, Francisco / Safah, Hana / Reynolds, Tim / Ibrahim, Moayed / Safa, Firas / Alfonso, Tina / Luk, Alfred / Mushatt, David M / Hu, Tony / Saba, Nakhle S

Leukemia research

2021 Volume 106, Page(s) 106582

MeSH term(s)	COVID-19/complications ; COVID-19/epidemiology ; COVID-19/mortality ; COVID-19/virology ; False Negative Reactions ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/epidemiology ; Hematologic Neoplasms/therapy ; Humans ; Kaplan-Meier Estimate ; Mortality ; SARS-CoV-2
Language	English
Publishing date	2021-04-24
Publishing country	England
Document type	Letter
ZDB-ID	752396-8
ISSN	1873-5835 ; 0145-2126
ISSN (online)	1873-5835
ISSN	0145-2126
DOI	10.1016/j.leukres.2021.106582
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1321: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.

Valecha, Gautam Kishore / Vennepureddy, Adarsh / Ibrahim, Uroosa / Safa, Firas / Samra, Bachar / Atallah, Jean Paul

Expert review of anticancer therapy

2017 Volume 17, Issue 1, Page(s) 47–59

Abstract: Introduction: Advanced non-small cell lung cancer (NSCLC) has been conventionally treated with cytotoxic chemotherapy with short-lived responses and significant toxicities. Monoclonal antibodies to programmed death-1 receptor (PD-1) and programmed death ...

Abstract	Introduction: Advanced non-small cell lung cancer (NSCLC) has been conventionally treated with cytotoxic chemotherapy with short-lived responses and significant toxicities. Monoclonal antibodies to programmed death-1 receptor (PD-1) and programmed death ligand 1 (PD-L1) have shown tremendous promise in the treatment of advanced NSCLC in various clinical trials. Areas covered: In this article, we will review the outcomes of various trials of anti-PD-1/anti-PD-L1 antibodies in the treatment of NSCLC. We will also discuss their mechanism of action and toxicities. Expert commentary: Anti-PD-1/PD-L1 antibodies offer several advantages including significant antitumor activity, induction of long lasting responses, and favorable safety profile. Several trials are now being conducted to evaluate their efficacy as first line agents as well as in combination with other agents. More research is also needed to identify other biomarkers, in addition to PD-L1 expression, that could more reliably predict response to these drugs, and aid in better patient selection.
MeSH term(s)	Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/pharmacology ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacology ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Biomarkers, Tumor/metabolism ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/immunology ; Humans ; Immunotherapy/methods ; Lung Neoplasms/drug therapy ; Lung Neoplasms/immunology ; Patient Selection ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology
Chemical Substances	Antibodies, Monoclonal ; Antineoplastic Agents ; B7-H1 Antigen ; Biomarkers, Tumor ; CD274 protein, human ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor
Language	English
Publishing date	2017-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2112544-2
ISSN	1744-8328 ; 1473-7140
ISSN (online)	1744-8328
ISSN	1473-7140
DOI	10.1080/14737140.2017.1259574
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5907: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review.

Safa, Houssein / Tamil, Monica / Spiess, Philippe E / Manley, Brandon / Pow-Sang, Julio / Gilbert, Scott M / Safa, Firas / Gonzalez, Brian D / Oswald, Laura B / Semaan, Adele / Diab, Adi / Chahoud, Jad

Journal of the National Cancer Institute

2020 Volume 113, Issue 5, Page(s) 532–542

Abstract: Background: Patient-reported outcomes (PROs) promote patient centeredness in clinical trials; however, in the field of rapidly emerging and clinically impressive immunotherapy, data on PROs are limited.: Methods: We systematically identified all ... ...

Abstract	Background: Patient-reported outcomes (PROs) promote patient centeredness in clinical trials; however, in the field of rapidly emerging and clinically impressive immunotherapy, data on PROs are limited. Methods: We systematically identified all immunotherapy approvals from 2011 through 2018 and assessed the analytic tools and reporting quality of associated PRO reports. For randomized clinical trials (RCTs), we developed a novel 24-point scoring scale: the PRO Endpoints Analysis Score based on 24 criteria derived from the recommendations of the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium. Results: We assessed 44 trial publications supporting 42 immunotherapy approvals. PROs were published for 21 of the 44 (47.7%) trial publications. Twenty-three trials (52.3%) were RCTs and 21 (47.7%) pertained to single-arm trials. The median time between primary clinical outcomes publications and their corresponding secondary PRO publications was 19 months (interquartile range = 9-29 months). Of the 21 PRO reports, 4 (19.0%) reported a specific hypothesis, and most (85.7%) used descriptive statistics. Three (3 of 21 [14.3%]) studies performed a control for type I error. As for RCTs, 14 of 23 (60.9%) published PRO data, including 13 (56.5%) that published a secondary dedicated manuscript. One-half of these 14 trials scored less than 13 points on the 24-point PRO Endpoints Analysis Score. The mean score was 12.71 (range = 5-17, SD = 3.71), and none met all the recommendations of the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium. Conclusions: Suboptimal reporting of PROs occurs regularly in cancer immunotherapy trials. Increased efforts are needed to maximize the value of these data in cancer immunotherapy development and approval.
MeSH term(s)	Drug Approval ; Humans ; Immunotherapy ; Neoplasms/drug therapy ; Patient Reported Outcome Measures ; Quality of Life
Language	English
Publishing date	2020-10-27
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Systematic Review
ZDB-ID	2992-0
ISSN	1460-2105 ; 0027-8874 ; 0198-0157
ISSN (online)	1460-2105
ISSN	0027-8874 ; 0198-0157
DOI	10.1093/jnci/djaa174
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.131: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma.

Niu, Alex / McDougal, April / Ning, Bo / Safa, Firas / Luk, Alfred / Mushatt, David M / Nachabe, Adeem / Zwezdaryk, Kevin J / Robinson, James / Peterson, Tim / Socola, Francisco / Safah, Hana / Hu, Tony / Saba, Nakhle S

Bone marrow transplantation

2020 Volume 55, Issue 12, Page(s) 2354–2356

MeSH term(s)	Aged ; Allografts ; COVID-19/diagnosis ; COVID-19/etiology ; COVID-19/therapy ; COVID-19 Nucleic Acid Testing/methods ; COVID-19 Serological Testing ; CRISPR-Cas Systems ; False Negative Reactions ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Immunization, Passive ; Immunocompromised Host ; Leukemia, B-Cell/complications ; Leukemia, B-Cell/immunology ; Leukemia, B-Cell/therapy ; Leukemia, Myeloid, Acute/complications ; Leukemia, Myeloid, Acute/immunology ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Pandemics ; SARS-CoV-2
Keywords	covid19
Language	English
Publishing date	2020-06-15
Publishing country	England
Document type	Case Reports ; Letter
ZDB-ID	632854-4
ISSN	1476-5365 ; 0268-3369 ; 0951-3078
ISSN (online)	1476-5365
ISSN	0268-3369 ; 0951-3078
DOI	10.1038/s41409-020-0972-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2168: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito